Κατεύθυνση Καρκίνος Πνεύμονα: Σύγχρονη Κλινικοεργαστηριακή Προσέγγιση και Έρευνα
Library of the School of Health Sciences

2015-07-16

2015

Παλαύρα Δήμητρα

Καθηγητής Κωνσταντίνος Συρίγος

Baseline serum albumin as a predictive biomarker for efficacy of Bevacizumab in non small cell lung cancer (NSCLC) patients

English

Lung cancer is the leading cause of cancer death in all developed countries.
The overall five-year survival is less than 15%. The mortality of lung cancer
is greater than the total mortality of breast, prostate and colon. The five
year survival rate has not changed significantly in recent decades, despite the
improvement of diagnostic tools, implementation of new therapeutics and
biomarkers.
It is important to find and use new biomarkers that will help in the
oncological approach, management and treatment, to provide the best possible
medical care and treatment to cancer patients.
Patients with histologically confirmed adenocarcinoma, men or women, were
eligible for this study. We have measured albumin and creatinine clearance in
blood serum before receiving chemotherapy with bevacizumab. In this study were
evaluated the patients, regardless of gender, who had > 3.5 mg/dl serum albumin
had a lower risk of death and better survival compared with those who had <3.5
mg/dl serum albumin.
The blood albumin serum has been found by studies that malnutrition is an
indicator. The hypoalbuminemia, which means the low price of albumin in blood
serum (value <3.5 mg / dl), is a risk factor of the patients with cancer, but
generally all critically ill patients. It is an important indicator of
morbidity and mortality.

Serum albumin, Bevacizumab, Non small cell lung cancer, Biomarker, Mortality

No

0

Yes

124

71

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/1314684